- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07637565
Artificial Intelligence-based Dietary Care System (AI DC-system)
June 3, 2026 updated by: National Taiwan University Hospital
Effectiveness of An Artificial Intelligence-based Dietary Care System for Distress From Altered Bowel Function and Quality of Life in Rectal Cancer Patients With Low Anterior Resection Syndrome
Patients with rectal cancer complicated by low anterior resection syndrome who undergo anal-preserving surgery may experience severe distress in daily life due to changes in bowel function, thus requiring significant post-discharge care support from healthcare professionals.
This study is a multicenter, non-blinded randomized controlled trial.
One hundred patients with rectal cancer complicated by low anterior resection syndrome are planned to be randomly assigned in a 1:1 ratio from the colorectal surgery outpatient clinics of National Taiwan University Hospital, its Cancer Center, and its Yunlin Branch.
They will be divided into a control group receiving routine dietary education and an experimental group receiving both routine dietary education and the use of an artificial intelligence-based dietary care system application.
The artificial intelligence-based dietary care system application will be used for approximately six months.
Three questionnaires will be administered at one month post-surgery (before intervention), three months post-surgery, and six months post-surgery.
The questionnaires will include: a demographic data sheet, a low anterior resection syndrome score, distress inventory from altered bowel functioning, and the European Organization for Research and Treatment of Cancer QLQ-30 Scale, to verify the effectiveness of the artificial intelligence-based dietary care system application in improving bowel disturbance and quality of life in patients with rectal cancer complicated by low anterior resection syndrome.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ling-Chun Lu, PhD
- Phone Number: 886-2-33665589
- Email: lulingchun@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 10617
- National Taiwn University, College of Medicine
-
Contact:
- Ling-Chun Lu, PhD
- Phone Number: 886-2-33665589
- Email: lulingchun@ntu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years.
- Clear consciousness with ability to communicate in Mandarin or Taiwanese.
- Histopathological confirmation of rectal adenocarcinoma.
- Undergoing radical rectal resection or such surgery combined with temporary stoma closure.
Exclusion Criteria:
- Diagnosis of other intestinal disorders, including intestinal tumors, bloating, obstruction, ulcerative colitis, or irritable bowel syndrome.
- Inability to access the internet.
- Inability to use a smartphone.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Artificial Intelligence-based Dietary Care System
Care program will conduct by Artificial Intelligence-based Dietary Care System.
|
|
|
Active Comparator: Routine care
Routine dietary education during hospitalization is provided via hospital-developed electronic materials accessible through QR code scanning.
|
Content covers postoperative dietary progression, nutritional supplementation, intake principles, and food avoidance.
The postoperative regimen typically advances through four stages-clear liquid, low-residue semi-liquid, low-residue soft, and regular diet-with most patients resuming normal intake within one month.
Guidance emphasizes high-protein, high-calorie foods, small frequent meals, and balanced nutrition, while advising avoidance of gas-producing, odorous, coarse-fiber, greasy, spicy, pickled, and dairy products.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Time Frame: Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
This 30-item instrument assesses cancer-related QoL across global health, five functional domains (physical, role, cognitive, emotional, and social), and nine symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulty) [22, 23].
Higher scores for functioning and global health indicate better QoL, whereas higher symptom scores denote greater symptom burden.
|
Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distress Inventory for Altered Bowel Functioning (DI-ABF)
Time Frame: Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
Developed by Lu et al., the 16-item DI-ABF measures distress arising from altered bowel functioning across three domains: daily life, emotional regulation, and social functioning, with higher scores reflecting greater distress.
Cut point 9.5 divided to be no bowel-related distress (0-9.5) and bowel-related distress (>9.5).
|
Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Low Anterior Resection Syndrome (LARS) Score
Time Frame: Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
Developed by Emmertsen and Laurberg [21], this tool evaluates five aspects of bowel dysfunction: flatus incontinence, fecal incontinence, bowel frequency, clustering, and urgency.
Scores range from 0 to 42, with higher scores indicating more severe symptoms.
Severity is categorized as no LARS (0-20), minor LARS (21-29), and major LARS (30-42).
|
Three-time frames are at one-month post-surgery (before intervention), three- months post-surgery, and six-months post-surgery.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
June 3, 2026
First Submitted That Met QC Criteria
June 3, 2026
First Posted (Actual)
June 10, 2026
Study Record Updates
Last Update Posted (Actual)
June 10, 2026
Last Update Submitted That Met QC Criteria
June 3, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 202603195RIND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
For privacy protection considerations, no individual praticipant data will be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AI Care Device
-
University of ManchesterUniversity of CambridgeRecruitingPrimary Care | Artificial Intelligence (AI)United Kingdom
-
Alexandria UniversityRecruitingPerioperative Nursing | Artificial Intelligence (AI) | Surgical Care | Nursing InformaticsEgypt
-
University of British ColumbiaWithdrawnCritical Care | Medical Device | User-Computer Interface | Physiologic MonitoringCanada
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)WithdrawnCritical Care | Medical Device | User-Computer Interface | Physiologic MonitoringCanada
-
Hospital Arnau de VilanovaCompletedRandomized Controlled Trial | Catheterization, Peripheral | Nursing Care | Vascular Access DeviceSpain
-
Fundacion Miguel ServetComplejo Hospitalario de NavarraNot yet recruitingVascular Access | Vascular Access Complication | Treatment Outcome | Nurse | Vascular Access Device | Nurse Based Care Management | Care Delivery
-
Medstar Health Research InstituteInova Schar Heart and VascularNot yet recruitingPalliative Care | Advanced Heart Failure | Left Ventricular Assist Device | Mechanical Circulatory SupportUnited States
-
University of PennsylvaniaCompletedPhysician Workflow | Transitions of Care | Electronic Medical Record | Large Language Model | Artificial Intelligence (AI)United States
-
Jagiellonian UniversityCompletedColonoscopy Diagnostic Techniques and Procedures | Quality Indicators, Health Care | Artificial Intelligence (AI)Poland
-
Jagiellonian UniversityRecruitingColonoscopy Diagnostic Techniques and Procedures | Quality Indicators, Health Care | Artificial Intelligence (AI)Poland
Clinical Trials on Artificial Intelligence-based Dietary Care System
-
Fujian Provincial HospitalRecruitingEarly Esophageal Cancer | Esophageal Cancer StageChina
-
Cairo UniversityCompletedOral Cancer | Leukoplakia | Oral Lichen Planus | Erythroplakia | Fordyce Granule | Leukoedemas, Oral | Lichenoid ReactionEgypt
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompletedProstatic Neoplasms | Lymphatic MetastasisChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompleted
-
Xiao-dong ZhuangRecruitingValvular Heart DiseaseChina
-
Technische Universität DresdenRecruitingInvasive Mechanical VentilationGermany, United States, Serbia, Spain, Switzerland
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingProstatic Neoplasms, Castration-ResistantChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingCancer | Lymphatic MetastasisChina
-
Fundacao ChampalimaudEuropean Commission; Cankado GmbH; Bocconi University; INESC TEC - Institute for... and other collaboratorsActive, not recruitingBreast CancerIsrael, Italy, Germany, Poland, Portugal